[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
IJRR Information::
For Authors::
For Reviewers::
News & Events::
Web Mail::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Hard Copy 2322-3243
Online 2345-4229
Online Submission
Now you can send your articles to IJRR office using the article submission system.



:: Volume 20, Issue 4 (10-2022) ::
Int J Radiat Res 2022, 20(4): 785-791 Back to browse issues page
Effects of maternal exposure to 131-I used for treatment of Graves' disease during childbearing age on chromosomal aberration and intellectual development of offspring
J. Zeng , J. Wang , Q. Guo , Y. Hou , Q. Lei , B. Yao , J. Lan , D. Zheng , Q. Feng , Z. Li , F. Chen , J. Xing , Y. Fang
Abstract:   (855 Views)
Background: Although radioiodine-131 (131I) has been widely used for the treatment of Graves' disease (GD), radiation is a potential risk factor for mutagenic abnormalities. This retrospective clinical study mainly aimed to investigate the influence of maternal exposure to 131I used for the treatment of GD prior to pregnancy on chromosomal aberration and intellectual development of offspring in China. Materials and Methods: In total, 69 children whose mothers received 131I for the treatment of GD during childbearing age were included. Data on the obstetric history, medical records, and the birth characteristics of the children were obtained. The thyroid function, thyroid ultrasound, chromosomal structure, and somatic and intellectual development of the children were measured. Results: In all 66 women, the range of the administered 131I was within 228.2 ± 70.3 MBq. The height and weight of all children were within the normal ranges, and one child was confirmed as having subclinical hypothyroidism. Two children were diagnosed with benign thyroid nodules, one child was diagnosed with thyroid cysts, and one child was confirmed as having several anechoic areas in both lobes of the thyroid gland. Chromosomal aberration was observed in one child. None of the children showed any abnormalities in somatic and/or intellectual development. Conclusion: This is the first study to confirm that 131I used for the treatment of GD prior to pregnancy does not significantly increase the risk of chromosomal aberration or impair the intellectual development of offspring.
Keywords: Graves' disease, 131-I treatment, chromosomal structure, intellectual development.
Full-Text [PDF 1917 kb]   (514 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
1. Subekti I and Pramono LA (2018) Current diagnosis and management of Graves's disease. Acta Med Indones, 50: 177-182.
2. King JR, Lachica R, Lee RH, et al. (2016) Diagnosis and management of hyperthyroidism in pregnancy: A Review. Obstet Gynecol Surv, 71: 675-685. [DOI:10.1097/OGX.0000000000000367] [PMID]
3. Kobaly K and Mandel SJ (2019) Hyperthyroidism and Pregnancy. Endocrinol Metab Clin North Am, 48: 533-545. [DOI:10.1016/j.ecl.2019.05.002] [PMID]
4. Bartalena L (2013) Diagnosis and management of Graves's disease: a global overview. Nat Rev Endocrinol, 9: 724-734. [DOI:10.1038/nrendo.2013.193] [PMID]
5. De Leo S, Lee SY, Braverman LE (2016) Hyperthyroidism. Lancet, 388: 906-918. [DOI:10.1016/S0140-6736(16)00278-6] [PMID]
6. Illouz F, Luton D, Polak M, et al. (2018) Graves' disease and pregnancy. Ann Endocrinol (Paris), 79: 636-646. [DOI:10.1016/j.ando.2018.08.004] [PMID]
7. Szumowski P, Abdelrazek S, Kociura Sawicka A, et al. (2015) Radioiodine therapy for Graves' disease - retrospective analysis of efficacy factors. Endokrynol Pol, 66: 126-131. [DOI:10.5603/EP.2015.0019] [PMID]
8. Hyer S, Kong A, Pratt B, et al. (2007) Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol (R Coll Radiol), 19: 83-86. [DOI:10.1016/j.clon.2006.11.005] [PMID]
9. Wang J and Qin L (2016) Radioiodine therapy versus antithyroid drugs in Graves' disease: a meta-analysis of randomized controlled trials. Br J Radiol, 89: 20160418. [DOI:10.1259/bjr.20160418] [PMID] []
10. Bourcigaux N, Rubino C, Berthaud I, et al. (2018) Impact on testicular function of a single ablative activity of 3.7 GBq radioactive iodine for differentiated thyroid carcinoma. Hum Reprod, 33: 1408-1416. [DOI:10.1093/humrep/dey222] [PMID]
11. Ceccarelli C, Bencivelli W, Morciano D, et al. (2001) 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab, 86: 3512-3515. [DOI:10.1210/jcem.86.8.7719] [PMID]
12. Hyer SL, Newbold K, Harmer CL (2010) Early and late toxicity of radioiodine therapy: detection and management. Endocr Pract, 16: 1064-1070. [DOI:10.4158/EP10170.RA] [PMID]
13. Okosieme OE, Taylor PN, Dayan CM (2020) Should radioiodine now be first line treatment for Graves' disease? Thyroid Res, 13: 3. [DOI:10.1186/s13044-020-00077-8] [PMID] []
14. Weiss W (2018) Chernobyl Thyroid Cancer: 30 Years of Follow-up Overview. Radiat Prot Dosimetry, 182: 58-61. [DOI:10.1093/rpd/ncy147] [PMID]
15. Fard-Esfahani A, Hadifar M, Fallahi B, et al. (2009) Radioiodine treatment complications to the mother and child in patients with differentiated thyroid carcinoma. Hell J Nucl Med, 12: 37-40.
16. Prunty JJ, Heise CD and Chaffin DG (2016) Graves' disease Pharmacotherapy in Women of Reproductive Age. Pharmacotherapy, 36: 64-83. [DOI:10.1002/phar.1676] [PMID]
17. Basbug M, Ozgun MT, Murat N, et al. (2010) Prenatal diagnosis of fetal hypothyroidism after maternal radioactive iodine exposure during pregnancy. J Clin Ultrasound, 38: 506-508. [DOI:10.1002/jcu.20737] [PMID]
18. Prinsen AK, Jansen J, Bakker WH, et al. (2006) Radioiodine therapy for women with Graves' disease and the risk of foetal hypothyroidism if they are later found to be pregnant. Ned Tijdschr Geneeskd, 150: 2845-2848.
19. Luz IR, Martins JR, Jerónimo M, et al. (2020) Neonates born to mothers with Graves' disease: 15 year experience of a pediatric endocrinology department. Acta Med Port, 33: 483-490. [DOI:10.20344/amp.12279] [PMID]
20. Suzuki K, Saenko V, Yamashita S, et al. (2019) Radiation-induced thyroid cancers: Overview of Molecular Signatures. Cancers (Basel), 11(9): 1290. [DOI:10.3390/cancers11091290] [PMID] []
21. Kitahara CM, Berrington de Gonzalez A, Bouville A, et al. (2019) Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism. JAMA Intern Med, 179: 1034-1042. https://doi.org/10.1001/jamainternmed.2019.5123 [DOI:10.1001/jamainternmed.2019.0981]
22. Read CH, Jr., Tansey MJ, Menda Y (2004) A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab, 89: 4229-4233. [DOI:10.1210/jc.2003-031223] [PMID]
23. [Gronich N, Lavi I, Rennert G, Saliba W (2020) Cancer risk after radioactive iodine treatment for hyperthyroidism: a cohort study. Thyroid, 30: 243-250. [DOI:10.1089/thy.2019.0205] [PMID]
24. Iijima S (2021) Effects of fetal involvement of inadvertent radioactive iodine therapy for the treatment of thyroid diseases during an unsuspected pregnancy. Eur J Obstet Gynecol Reprod Biol, 259: 53-59. [DOI:10.1016/j.ejogrb.2021.02.003] [PMID]
25. Hyer S, Pratt B, Newbold K, et al. (2009) Outcome of pregnancy after exposure to radioiodine In Utero. Endocr Pract, 1-10. [DOI:10.4158/EP10237.RA] [PMID]
26. Hall EJ (2009) Radiation biology for pediatric radiologists. Pediatr Radiol, 39(1): S57-64. [DOI:10.1007/s00247-008-1027-2] [PMID]
27. Zhang LH, Li JY, Tian Q, et al. (2016) Follow-up and evaluation of the pregnancy outcome in women of reproductive age with Graves' disease after 131Iodine treatment. J Radiat Res, 57: 702-708. [DOI:10.1093/jrr/rrw049] [PMID] []
28. Guan L, Chen G, Zhang J, et al. (2016) The preliminary clinical observation and analysis of childbearingage women with a history of iodine-131 treatment for Graves' disease. Biosci Trends, 10: 307-314. [DOI:10.5582/bst.2016.01008] [PMID]
Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Zeng J, Wang J, Guo Q, Hou Y, Lei Q, Yao B, et al . Effects of maternal exposure to 131-I used for treatment of Graves' disease during childbearing age on chromosomal aberration and intellectual development of offspring. Int J Radiat Res 2022; 20 (4) :785-791
URL: http://ijrr.com/article-1-4465-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 20, Issue 4 (10-2022) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.06 seconds with 50 queries by YEKTAWEB 4657